Rethinking Alzheimer's Treatment

The prevailing approach to Alzheimer's treatment, focusing on increasing acetylcholine levels, may actually worsen cognitive decline for patients. Research suggests that beta amyloid plaques are a response to underlying issues rather than the root cause of the disease. This shift in understanding has led to significant reconsideration of treatment strategies, as evidenced by major pharmaceutical companies stepping back from developing new Alzheimer's drugs.